What Researchers Did
Researchers conducted a systematic literature review to evaluate predisposing risk factors, preventative measures, and treatment options for cancer treatment-induced haemorrhagic cystitis.
What They Found
Haemorrhagic cystitis (HC) was reported in up to 20% of patients receiving pelvic radiotherapy and up to 30% of those treated with cyclophosphamide or bacillus Calmette-Guérin. Mesna, hyperhydration, and bladder irrigation are common but not always effective prophylactic measures. Evidence for cranberry juice as prevention and sodium pentosanpolysulphate as treatment is limited.
What This Means for Canadian Patients
Canadian patients undergoing cancer treatments like pelvic radiotherapy or chemotherapy may experience haemorrhagic cystitis, a serious complication. This review helps clinicians understand risk factors and available, though sometimes limited, preventative and treatment strategies to manage this condition.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The review highlights limitations in the existing literature, including variability in study design, quality, causal agent types, bleeding grades, and definition criteria for haemorrhagic cystitis.